Given that C3 is the convergent point of all three complement cascades, leading to C3aR and C5aR anaphylatoxin receptors signaling, the potential targeting of C3 is a current goal in the development of complement-based therapeutics for treating chronic inflammatory and autoimmune diseases [60]. The gene discussed is C3; the disease is autoimmune disease.